JP2007176804A - Medicine or healthy food having slimming action - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicine or a healthy food having slimming actions. <P>SOLUTION: The medicine or healthy food has the slimming actions and comprises coenzyme Q10 as an active ingredient. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a medicament having a slimming action comprising coenzyme Q10 as an active ingredient, and a health food having a slimming action comprising coenzyme Q10.

  Ubiquinone (abbreviation: UQ) is one of the components of the electron transport system that exists in the inner membrane of mitochondria and the cell membrane of prokaryotes. This substance, also called coenzyme Q, has a quinone skeleton and has a relatively long isoprene side chain, but in humans the number of repeating isoprene side chains is 10, It is often referred to as Q (10), coenzyme Q10, CoQ10 and the like (this substance may be referred to as “coenzyme Q10” in this specification). Coenzyme Q10 is synthesized in vivo and is ingested in small amounts from meals, but is generally known to be gradually deficient during normal aging. It has also been suggested that a decrease in the amount of coenzyme Q10 in the body contributes directly or indirectly to aging, and that aging can be delayed by increasing the amount of coenzyme Q10 in the body.

  Coenzyme Q10 has been suggested to be applicable for various pharmaceutical uses. For example, improvement of symptoms of congestive heart failure (Clin. Investig., 71, pp.134-136, 1993), efficacy against hypertension (Mol. Aspects Med., 15, pp.257-263, 1994; Mol. Aspects Med., 15, pp.265-272, 1994; Eur. J. Clinical Nutr., 56, pp.1137-1142, 2002), treatment of muscular dystrophy (Biochim. Biophys. Acta, 1271, pp.281-286, 1995), treatment of Huntington's disease (Ann. Neurol., 41, pp. 160-165, 1997), treatment of Parkinson's disease (Arch. Neurol., 59, pp.1541-1550, 2002), etc. . Coenzyme Q10 is also used as a health food such as supplements to prevent Alzheimer's disease, Parkinson's disease, or Huntington's disease, prevent cancer, prevent aging, improve skin wrinkles, recover from fatigue, and prevent arteriosclerosis. Or, it is widely taken as a component of health food for the purpose of preventing diabetes. However, no slimming effect has been known for Coenzyme Q10.

  The subject of this invention is providing the active ingredient of the pharmaceutical which has a slimming effect, and the component of the health food which has the said effect | action.

  As a result of intensive studies to solve the above problems, the present inventors have found that coenzyme Q10 has a slimming action in mammals including humans, and have completed the present invention.

That is, the present invention provides a medicament having a slimming action and comprising coenzyme Q10 as an active ingredient.
Further, according to the present invention, a health food having a slimming action and containing coenzyme Q10 is provided.

Another aspect provides the use of Coenzyme Q10 for the manufacture of the above medicament or health food.
From yet another aspect, the present invention provides a method for slimming a mammal comprising the step of orally or parenterally administering an effective amount of coenzyme Q10. According to a preferred aspect of the present invention, there is provided the above-mentioned method for administration using the above-mentioned medicine or the above-mentioned health food.

  Coenzyme Q10 contained in the pharmaceutical or health food of the present invention has a slimming action on mammals, and is effective in preventing obesity, suppressing obesity and maintaining or reducing body weight in mammals including humans. In particular, since the pharmaceutical or health food of the present invention can maintain or reduce the body weight without restricting the calorie intake, it is useful for the prevention of lifestyle-related diseases such as hypertension, diabetes, or hyperlipidemia.

Since the medicine containing coenzyme Q10 (2,3-dimethyl-5-methyl-6-decaprenyl-1,4-benzoquinone) contained in the medicine or health food of the present invention as an active ingredient has already been used clinically, You may use the medicine already marketed as a medicine of invention. For example, “Enateam” (Nippon Shinyaku Co., Ltd.), “Neuquinone” (Eisai Co., Ltd.), “Neucool” (Kyowa Hakko Kogyo Co., Ltd.) and the like are provided as ubidecarenone preparations. Further, since being provided many also health foods containing Coenzyme Q _10, it may be used those health food as a health food of the present invention.
It can be easily confirmed by those skilled in the art that the coenzyme Q10 contained in the pharmaceutical or health food of the present invention has a slimming action by the method specifically described in the Examples.

  The administration route and dose of the medicament of the present invention are not particularly limited, but when administered to humans, for example, the dose in the range of about 10 to 1,000 mg as the weight of coenzyme Q10 which is an active ingredient per day for adults Can be selected. As an administration route, any of oral and parenteral administration routes can be selected. Preferably, the dose is selected from the range of about 50 to 300 mg and orally administered. However, the above dose can be appropriately increased or decreased according to various conditions such as the patient's age, weight or symptoms, route of administration, desired degree of slimming action, and the doctor selects an appropriate dose. it can. In the medicament of the present invention, the above-mentioned daily dose may be administered once per day, but the daily dose may be divided into about 2 to 3 times.

  Although coenzyme Q10 itself may be used as the medicament of the present invention, preferably, the medicament of the present invention contains coenzyme Q10 which is an active ingredient and one or more pharmaceutically acceptable additives for pharmaceutical preparations. It is provided in the form of a pharmaceutical composition. The medicament of the present invention may be administered as a pharmaceutical composition for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, or liquids. Alternatively, it may be administered as a pharmaceutical composition for parenteral administration such as an injection or infusion, suppository, nasal drop, or eye drop for intravenous, intramuscular or subcutaneous administration. Examples of the additives for preparation include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, dyes, diluents, bases, solubilizers or solubilizers, isotonic agents, A pH regulator, a stabilizer, a propellant, an adhesive or the like can be used, and an appropriate one can be selected and used according to the form of the pharmaceutical composition.

As used herein, the term “medicament” encompasses any embodiment for administering coenzyme Q10 for slimming from a medical standpoint, such as preventing or inhibiting obesity for the prevention and / or treatment of disease. In addition to its use as a medicine prescribed in the Pharmaceutical Affairs Law, it includes use as a quasi-drug.
In addition, the term “food” in this specification means food defined by the Food Sanitation Law, and all except pharmaceuticals and quasi drugs prescribed in the Pharmaceutical Affairs Law (Act No. 145 of 1960). Means food and drink. In this specification, the term “health food” means food and drink used for disease prevention and health maintenance. The health food of the present invention exerts a slimming action, such as prevention and control of obesity, maintenance or reduction of body weight, reduction of visceral fat, etc. due to lifestyle diseases such as hypertension, hyperlipidemia, diabetes, etc. It is a food that can achieve disease prevention and health maintenance. Preferred food forms include beverages, confectionery, processed foods and the like, but are not limited thereto.

  The pharmaceutical or health food of the present invention can be applied to mammals including humans. Although the kind of mammal animals other than a human is not specifically limited, For example, in addition to pet animals, such as a cat and a dog, livestock animals, such as a cow and a horse, etc. are included. A preferred application target is a human or a pet animal (such as a dog or a cat). When the medicament of the present invention is administered to livestock and the like, it is desirable to incorporate coenzyme Q10 in the feed. Moreover, what is necessary is just to mix | blend coenzyme Q10 with a dog food or a cat food etc. when administering the pharmaceutical of this invention with respect to a pet animal. In addition, livestock feed and pet animal food blended with coenzyme Q10 as described above can also be used as health food.

  The medicament or health food of the present invention has a slimming action, and acts such as maintenance or reduction of body weight, prevention or suppression of obesity, or prevention, suppression or reduction of visceral fat accumulation in mammals including humans. Can be demonstrated. In this specification, “slimming” or a synonym thereof should be interpreted not only in terms of weight reduction but also in the broadest sense including the above-described effects, and should not be interpreted in a limited manner in any sense.

Hereinafter, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples.
Example 1
Coenzyme Q10 (manufactured by Kougen Co., Ltd.) was dissolved in corn oil and dissolved uniformly in a 45 ° C. water bath with a magnetic stirrer to prepare a coenzyme Q10 solution.
Twenty-five 5-week-old female rats were purchased from CLEA Japan. After the rats were bred for 1 week, 20 out of 26 rats were used as 6-week-old rats. The coenzyme Q10 administration group was orally administered with a coenzyme Q10 solution (10 animals were used as a group at a dose of 1,000 mg / kg / day). The rat body weight at the start of oral administration was 116-126 g. Animals were raised under conditions of temperature: 22 ± 3 ° C .; humidity: 50 ± 20%; ventilation: 10 times per hour (all fresh air); lighting: 12 hours per day. MF mash (manufactured by Oriental Yeast Co., Ltd.) was freely given from the serving bottle. The water was filtered through a rapid filter unit, sterilized with sodium hypochlorite, and further UV-irradiated in a plastic bottle and freely given to animals. A solvent administration group was provided as a negative control (10 animals).

  Oral administration of coenzyme Q10 specimen solution to animals was continued for 31 days. This oral administration method uses the same route of administration as clinical human administration, and is also a method commonly used in repeated dose toxicity studies of pharmaceuticals. Specifically, the coenzyme Q10 sample solution was maintained at 45 ° C in a water bath to visually check the sample solution for uniformity and physical and chemical deterioration, and then stirred with a stirrer bar in a 40 ° C water bath. Then, it was injected into a syringe and forcibly administered from the syringe into the stomach of the animal with a sonde. Administration was performed at the same time every day throughout the study. In the 1,000 mg / kg / day administration group, the coenzyme Q10 concentration was adjusted to 250 mg / ml and orally administered to rats at a volume of 4 ml / kg. Body weight was measured at the start of coenzyme Q10 administration and once weekly. The average body weight of each group of animals was determined from the measurements of all animals in each group. The results are shown in Table 1. Compared to the control group, there was almost no change in body weight in the coenzyme Q10 administration group.

  In addition, the amount of food was measured continuously for 7 days from the first week to the third week, and continuously for 4 days for the fourth week. Daily food intake for each individual was calculated for each week, and the average food intake (g / rat / day) for each group was calculated from their individual data. The results are shown in Table 2.

  The results are summarized in Table 3. The amount of food in the first week and the fourth week was analyzed by Dunnet's multiple comparison test, and it was found that p <0.01 (indicated by * in Table 3) significantly increased. In the coenzyme Q10 administration group, there was no change in body weight compared to the control group, suggesting that the body weight decreased if the diet level was controlled at a certain level.

Example 2
Mice were used as experimental animals, and coenzyme Q10 solution was orally administered in the same manner as in Example 1 (10 animals were used as a group at a dose of 1,000 mg / kg / day). The administration period was 21 days, and administration was performed at the same time every day. A solvent administration group was provided as a negative control. As a result, in the third week, the coenzyme Q10 administration group increased the amount of food by 7% compared with the control group, but almost no change in body weight was observed.

Claims (6)

A medicament having a slimming action, comprising coenzyme Q10 as an active ingredient. The medicament according to claim 1, which is used for mammals including humans. The medicine according to claim 2, wherein the mammal is a human or a mammal pet animal. The medicine according to claim 3, wherein the mammal pet animal is a dog or a cat. A health food that has a slimming effect and contains coenzyme Q10. The food according to claim 2, which is in the form of a beverage, confectionery, or processed food.